Dec 19 (Reuters) - Janssen Sciences Ireland UC -
* Press release - Positive results from first Phase III studies of investigational two-drug HIV treatment regimen
* Janssen Sciences Ireland UC - Rilpivirine (Janssen) and Dolutegravir (ViiV Healthcare) met primary endpoint of non inferiority at week 48
* Janssen Sciences Ireland UC - Anticipated that regulatory submissions for Rilpivirine and Dolutegravir as a single tablet will be made in 2017 Source text for Eikon: ID:nCNWFff1xa Further company coverage: JNJ.N